US2018369376A1PendingUtilityA1

Compositions and methods for beta-glucan immunotherapy

66
Assignee: BIOTHERA INCPriority: Apr 30, 2012Filed: Aug 31, 2018Published: Dec 27, 2018
Est. expiryApr 30, 2032(~5.8 yrs left)· nominal 20-yr term from priority
Inventors:William J. GrossmanMary A. AntonysamyRichard M. WalshMariana I. NelsonNandita BoseMichael E. DanielsonKyle S. Michel
A61K 39/39558A61K 39/39A61P 35/02G01N 2400/24A61P 35/00G01N 33/554C07K 16/12A61P 43/00G01N 33/53A61K 2039/55583A61K 39/39583A61K 47/6835A61K 31/716G01N 33/56966A61P 37/04A61K 45/06C07K 16/14A61K 39/39575A61K 39/395A61P 37/02G01N 33/5047
66
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

This disclosure describes, in one aspect, a composition that includes a β-glucan component and an antibody component that specifically binds to the β-glucan. In another aspect, this disclosure describes a method of increasing a subject's response to β-glucan immunotherapy. Generally, the method includes identifying the subject as a low binder of β-glucan and administering to the subject a composition that comprises a β-glucan moiety conjugated to the therapeutic antibody. In some cases, the therapeutic antibody can be an anti-tumor antibody.

Claims

exact text as granted — not AI-modified
1 . A composition comprising:
 a soluble β-glucan component; and   an antibody component that specifically binds to the soluble β-glucan.   
     
     
         2 . The composition of  claim 1  wherein the soluble β-glucan is derived from yeast. 
     
     
         3 . The composition of  claim 1  wherein the soluble β-glucan comprises a β-1,3/1,6 glucan. 
     
     
         4 . The composition of  claim 1  wherein the soluble β-glucan comprises β(1,6)-[poly-(1,3)-D-glucopyranosyl]-poly-β(1,3)-D-glucopyranose. 
     
     
         5 . The composition of  claim 1  wherein the antibody component comprises a monoclonal antibody that specifically binds to the soluble β-glucan. 
     
     
         6 . The composition of  claim 5  wherein the monoclonal antibody comprises BfD I, BfD II, BfD III, or BfD IV. 
     
     
         7 . The composition of  claim 1  wherein the soluble β-glucan component and the antibody component are provided in a single formulation. 
     
     
         8 . The composition of  claim 1  wherein the soluble β-glucan component and the antibody component are provided in separate formulations. 
     
     
         9 . The composition of  claim 1  further comprising an anti-tumor antibody. 
     
     
         10 - 31 . (canceled)

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.